Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Cummings, Steven R., Martin, Javier San, McClung, Michael R., Siris, Ethel S., Eastell, Richard, Reid, Ian R., Delmas, Pierre, Zoog, Holly B. +8 more·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0809493

Cited by (1,006)

Items 201–300 of 1,006

  1. Update on Estrogens and the Skeleton
    Sundeep Khosla · 2010 · The Journal of Clinical Endocrinology & Metabolism
  2. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics
    Albrecht Werner Popp, Philippe K. Zysset, Kurt Lippuner · 2015 · Osteoporosis International
  3. 2018 update of French recommendations on the management of postmenopausal osteoporosis
    Karine Briot, Christian Roux, Thierry Thomas, Hubert Blain, Daniel Buchon, Roland D Chapurlat, Françoise Debiais, J.-M. Féron, Jean Bernard Gauvain, Pascal Guggenbuhl et al. · 2018 · Joint Bone Spine
  4. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
    Christian Roux, Lorenz Christian Hofbauer, Pei‐Ran Ho, John Dennis Wark, M. Carola Zillikens, Astrid Fahrleitner‐Pammer, Federico Gustavo Hawkins, Maïté Micaëlo, Salvatore Minisola, Νικόλαος Παπαϊωάννου et al. · 2013 · Bone
  5. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
    Serge Ferrari, Serge Ferrari · 2010 · Osteoporosis International
  6. The kidney and bisphosphonates
    Paul D. Miller · 2011 · Bone
  7. Bone Health and Osteoporosis Prevention and Treatment
    MARCUS MUÑOZ, KATHLEEN ROBINSON, Amal A Shibli-Rahhal · 2020 · Clinical Obstetrics & Gynecology
  8. RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation
    Chen, Xiao, Zhi, Xin, Wang, Jun, Su, Jiacan · 2018 · Bone Research
  9. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
    Michael R. McClung, Steven Boonen, Ove Törring, Christian Roux, René Rizzoli, Henry G. Bone, Claude-Laurent Benhamou, Willem Frederik Lems, Salvatore Minisola, Johan Halse et al. · 2011 · Journal of Bone and Mineral Research
  10. Biomarkers of the Osteoprotegerin Pathway
    Wolfgang Lieb, Philimon Nyakauru Gona, Martin G. Larson, Joseph M. Massaro, Izabella Lipinska, John F. Keaney, Jian Rong, Diane Corey, Udo Hoffmann, Caroline S. Fox et al. · 2010 · Arteriosclerosis Thrombosis and Vascular Biology
  11. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures
    Willem Frederik Lems, Karsten Dreinhöfer, Heike Annette Bischoff-Ferrari, Michael Blauth, Edward J. Czerwinski, José António Pereira da Silva, Antonio Herrera, Pierre J Hoffmeyer, Tore Kristian Kvien, Ghassan Maalouf et al. · 2016 · Annals of the Rheumatic Diseases
  12. Pathophysiology and New Strategies for the Treatment of Legg-Calvé-Perthes Disease
    Harry K.W. Kim · 2012 · Journal of Bone and Joint Surgery
  13. Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs
    Willem Frederik Lems, Hennie G. Raterman · 2017 · Therapeutic Advances in Musculoskeletal Disease
  14. New understanding and treatments for osteoporosis
    Gherardo Mazziotti, John Paul Bilezikian, ERNESTO M. CANALIS, Daniela Cocchi, A. Giustina · 2011 · Endocrine
  15. NF-κB: master regulator of cellular responses in health and disease
    Alexander Hoffmann, Genhong Cheng, David Baltimore · 2025 · Immunity & Inflammation
  16. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
    Felicia Cosman, Edward Michael Lewiecki, Richard Eastell, Peter Robert Ebeling, Suzanne M. Jan de Beur, Bente Lomholt Langdahl, Yumie Rhee, Ghada El‐Hajj Fuleihan, Douglas P. Kiel, John T. Schousboe et al. · 2024 · Journal of Bone and Mineral Research
  17. Trial Watch: Monoclonal antibodies in cancer therapy
    Lorenzo Galluzzi, Erika Vacchelli, Wolf H. Fridman, Jérôme Galon, Catherine Sautès‐Fridman, Éric Tartour, Jessica Zucman‐Rossi, Laurence Zitvogel, Guido Kroemer · 2012 · OncoImmunology
  18. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
    Ende Zhao, Lin Wang, Jinlu Dai, Ilona Kryczek, Shuang Wei, Linda Vatan, Saleh Altuwaijri, Tim D. Sparwasser, Guobin Wang, Evan T. Keller et al. · 2012 · OncoImmunology
  19. Pharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
    Filippo Migliorini, Giorgia Colarossi, Alice Baroncini, Jörg Eschweiler, Markus Tingart, Nicola Maffulli · 2020 · Expert Review of Clinical Pharmacology
  20. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
    Jacques P. Brown, Christian Roux, Ove Törring, Pei‐Ran Ho, Jens‐Erik Beck Jensen, Nigel Leslie Gilchrist, Christopher P. Recknor, Matt Austin, Andrea Wang, Andreas Grauer et al. · 2012 · Journal of Bone and Mineral Research
  21. Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics
    Adejuyigbe, Babapelumi, Kallini, Julie, Chiou, Daniel, Kallini, Jennifer R. · 2023 · International Journal of Molecular Sciences
  22. Denosumab: an Emerging Therapy in Pediatric Bone Disorders
    Alison M. Boyce · 2017 · Current Osteoporosis Reports
  23. Melatonin: Another avenue for treating osteoporosis?
    Tian Xiang Li, Shuai Jiang, Chenxi Lu, Wenwen Yang, Zhi Ping Yang, Wei Hu, Zhenlong Xin, Yang Yang · 2018 · Journal of Pineal Research
  24. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX
    Eugene Vincent McCloskey, Helena Johansson, Anders Odén, Matt Austin, Ethel S. Siris, Andrea Wang, Edward Michael Lewiecki, Roman S Lorenc, Cesar R. Libanati, John А. Kanis · 2012 · Journal of Bone and Mineral Research
  25. Effect of osteoporosis medications on fracture healing
    Vishal V. Hegde, J. E. Jo, Panagiota Andreopoulou, Joseph M. Lane · 2015 · Osteoporosis International
  26. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis
    Piet Geusens · 2012 · Therapeutic Advances in Musculoskeletal Disease
  27. The effect of exercise intensity on bone in postmenopausal women (part 2): A meta-analysis
    Melanie Kistler-Fischbacher, Benjamin K. Weeks, Belinda R. Beck · 2020 · Bone
  28. New Frontiers in Osteoporosis Therapy
    Cheng Cheng, Kelly Lee Wentworth, Dolores Shoback · 2019 · Annual Review of Medicine
  29. Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
    Paul D. Miller, Rachel B. Wagman, Munro Peacock, Edward Michael Lewiecki, Michael A. Bolognese, Richard L. Weinstein, Beiying Ding, Javier San Martín, Michael R. McClung · 2010 · The Journal of Clinical Endocrinology & Metabolism
  30. RANKL/RANK—beyond bones
    Reiko Hanada, Toshikatsu Hanada, Verena Sigl, Daniel Schramek, Josef Martin Penninger · 2011 · Journal of Molecular Medicine
  31. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
    Timothy P. LaBranche, Michael I. Jesson, Zaher A. Radi, Chad E. Storer, Julia A. Guzova, Sheri L. Bonar, Janice Thompson, Fernando A. Happa, Zachary S. Stewart, Yutian Zhan et al. · 2012 · Arthritis & Rheumatism
  32. Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
    Kenneth G. Saag, Nicola Pannacciulli, Piet Geusens, Jonathan Derrick Adachi, Osvaldo Daniel Messina, Jorge Morales‐Torres, Ronald D. Emkey, Peter W Butler, Xiang Yin, Willem Frederik Lems · 2019 · Arthritis & Rheumatology
  33. Denosumab for the treatment of osteoporosis
    Sarah Zaheer, Meryl Susan LeBoff, Edward Michael Lewiecki · 2015 · Expert Opinion on Drug Metabolism & Toxicology
  34. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
    Henry G. Bone, DW Dempster, John A. Eisman, S. L. Greenspan, Michael R. McClung, Toshitaka Nakamura, S. E. Papapoulos, Weichung Joe Shih, Andrea Rybak-Feiglin, Arthur C. Santora et al. · 2014 · Osteoporosis International
  35. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS
    Athanasios D. Anastasilakis, Jessica Pepe, Nicola Napoli, Andrea Palermo, Christos Magopoulos, Aliya Aziz Khan, M. Carola Zillikens, Jean-Jacques Body · 2021 · The Journal of Clinical Endocrinology & Metabolism
  36. Structural and Functional Insights of RANKL–RANK Interaction and Signaling
    Changzhen Liu, Thomas S. Walter, Peng Huang, Shiqian Zhang, Xuekai Zhu, Ying Wu, Lucy R. Wedderburn, Peifu Tang, Raymond J. Owens, David Ian Stuart et al. · 2010 · The Journal of Immunology
  37. New targets for intervention in the treatment of postmenopausal osteoporosis
    Edward Michael Lewiecki · 2011 · Nature Reviews Rheumatology
  38. Percutaneous Doxycycline Treatment of Aneurysmal Bone Cysts With Low Recurrence Rate: A Preliminary Report
    William E. Shiels, Joel L. Mayerson · 2013 · Clinical Orthopaedics and Related Research
  39. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
    Nelson B. Watts, Christian Roux, John F. Modlin, Jacques P. Brown, A. Daniels, Simon M. Jackson, S. Y. Smith, D. J. Zack, Lifen Zhou, Andreas Grauer et al. · 2011 · Osteoporosis International
  40. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic
    Lilio Hu, Angelodaniele Napoletano, Michele Provenzano, Carlo Garofalo, Claudia Bini, Giorgia Comai, Gaetano La Manna · 2022 · International Journal of Molecular Sciences
  41. Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials
    Ann V. Schwartz, Anne L. Schafer, Andrew B. Grey, Eric Vittinghoff, Lisa Palermo, Li‐Yung Lui, Robert B. Wallace, Steven Ron Cummings, Dennis M. Black, Douglas C. Bauer et al. · 2013 · Journal of Bone and Mineral Research
  42. Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data
    David W. Dempster, Cheryl L. Lambing, Paul J. Kostenuik, Andreas Grauer · 2012 · Clinical Therapeutics
  43. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance
    Imran S. Khan, Maria L. Mouchess, Menglei Zhu, Bridget E. Conley, Kayla J. Fasano, Yafei Hou, Lawrence H. Fong, Maureen A. Su, Mark Stuart Anderson · 2014 · The Journal of Experimental Medicine
  44. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015
    Aliya Aziz Khan, Archie D. Morrison, Angela M. Cheung, Wael Hashem, Juliet Elizabeth Compston · 2015 · Osteoporosis International
  45. Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy
    Chris P. Recknor, Edward J. Czerwinski, Henry G. Bone, Sydney Lou Bonnick, Neil Binkley, Santiago Palacios, Alfred H. Moffett, Suresh R Siddhanti, Irene Ferreira, Prayashi Ghelani et al. · 2013 · Obstetrics and Gynecology
  46. A Magnetic‐Field Guided Interface Coassembly Approach to Magnetic Mesoporous Silica Nanochains for Osteoclast‐Targeted Inhibition and Heterogeneous Nanocatalysis
    Li Juan Wan, Hongyuan Song, Xiao Chen, Yu Zhang, Qin Yue, Panpan Pan, Jiacan Su, Ahmed Abdel Fattah Elzatahry, Yonghui Deng · 2018 · Advanced Materials
  47. An update on therapies for the treatment of diabetes-induced osteoporosis
    Sahar Mohsin, May M.Y.H. Baniyas, Reem Saif Al Darmaki, Kornélia Tekes, Huba Kalász, Ernest A Adeghate · 2019 · Expert Opinion on Biological Therapy
  48. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals
    Kamyar Kalantar‐Zadeh, Anuja Pradip Shah, Uyen Duong, Rulin C. Hechter, Ramanath B. Dukkipati, Csaba Pal Kovesdy · 2010 · Kidney International
  49. Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
    Luigi Ferrucci, Marta Baroni, Anna Ranchelli, Fulvio Lauretani, Marcello Giuseppe Maggio, Patrizia Mecocci, Carmelinda Ruggiero · 2014 · Current Pharmaceutical Design
  50. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review
    Suad Aljohani, Riham M. Fliefel, Jacob Ihbe, Jan Kühnisch, Michael Ehrenfeld, Sven Otto · 2017 · Journal of Cranio-Maxillofacial Surgery
  51. Diagnosis and Management of Osteoporosis.
    Michael P Jeremiah, Brian Unwin, Mark H. Greenawald, Vincent E. Casiano · 2015 · PubMed
  52. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial
    Bente Lomholt Langdahl, Christence Stubbe Teglbjærg, Pei‐Ran Ho, Roland D Chapurlat, Edward J. Czerwinski, David L. Kendler, Jean‐Yves Reginster, Alan Kivitz, Edward Michael Lewiecki, Paul D. Miller et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism
  53. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
    Harjit Pal Bhattoa, Samuel D Vasikaran, Ioulia Trifonidi, Georgia Kapoula, Giovanni Lombardi, Niklas Rye Jørgensen, Richard Pikner, Masakazu Miura, Roland D Chapurlat, Mickaël Hiligsmann et al. · 2025 · Osteoporosis International
  54. Mechanisms and treatment of hypercalcemia of malignancy
    Gregory A. Clines · 2011 · Current Opinion in Endocrinology Diabetes and Obesity
  55. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
    Panagiotis G. Anagnostis, Stavroula Α. Paschou, Gesthimani Mintziori, Iuliana Ceauşu, Herman T. Depypere, Irene V. Lambrinoudaki, Alfred Otto Mueck, Faustino Ramón Pérez-López, Margaret Rees, Levent Mehmet Senturk et al. · 2017 · Maturitas
  56. Management of Osteoporosis in CKD
    Pascale Khairallah, Thomas L. Nickolas · 2018 · Clinical Journal of the American Society of Nephrology
  57. Medication-related osteonecrosis of the jaw: A literature review
    Shinichiro Kuroshima, Muneteru Sasaki, Takashi Sawase · 2019 · Journal of Oral Biosciences
  58. Roles of osteoclasts in alveolar bone remodeling
    Maiko Omi, Yuji M. Mishina · 2022 · genesis
  59. Myeloma bone disease: Pathophysiology and management
    R. Silbermann, G. Roodman · 2013 · Journal of Bone Oncology
  60. Hypocalcemia Post Denosumab in Patients with Chronic Kidney Disease Stage 4-5
    Vatsa Dave, Cherie Ying Chiang, Jane C. Booth, Peter F. Mount · 2015 · American Journal of Nephrology
  61. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis
    Ejaz Pathan, Sonya Abraham, Elizabeth Van Rossen, Robin H. Withrington, Andrew Keat, Peter J Charles, Erin Paterson, Muslima Chowdhury, C McClinton, Peter Charles Taylor · 2012 · Annals of the Rheumatic Diseases
  62. RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk
    Elizabeth J. Samelson, Paul D. Miller, Claus Christiansen, Nadia S Daizadeh, Luanda P. Grazette, Mary S. Anthony, Ogo I. Egbuna, Andrea Wang, Suresh R Siddhanti, Angela M. Cheung et al. · 2013 · Journal of Bone and Mineral Research
  63. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw
    JE Compston · 2011 · Osteoporosis International
  64. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study
    Richard Eastell, Shinichi Nagase, Michiyo Ohyama, Maria Small, James P. C. Sawyer, Steven Boonen, Tim D. Spector, Tomohiro Kuwayama, Steve Deacon · 2011 · Journal of Bone and Mineral Research
  65. Osteoporosis: the current status of mesenchymal stem cell-based therapy
    Jitrada Phetfong, Tanwarat Sanvoranart, Kuneerat Nartprayut, Natakarn Nimsanor, Kanokwan Seenprachawong, Virapong Prachayasittikul, Aungkura Supokawej · 2016 · Cellular & Molecular Biology Letters
  66. The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
    Anne F. de Groot, Natasha M. Appelman‐Dijkstra, Sjoerd H. van der Burg, Judith R. Kroep · 2017 · Cancer Treatment Reviews
  67. Osteoporosis in men
    Peter Robert Ebeling · 2013 · Current Opinion in Rheumatology
  68. Osteoporosis
    Anna L. Golob, Mary B. Laya · 2015 · Medical Clinics of North America
  69. Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014
    Felicia Cosman, J. H. Krege, Anne C. Looker, John T. Schousboe, B. Fan, Neda Sarafrazi, J. Shepherd, Kelly Krohn, Philipp Steiger, Kevin E. Wilson et al. · 2017 · Osteoporosis International
  70. Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (Review)
    Li Tian, Xijie Yu · 2015 · Molecular Medicine Reports
  71. Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
    Heike Hoyer‐Kuhn, Christian Netzer, Friederike Koerber, Eckhard Schöenau, Oliver Semler · 2014 · Orphanet Journal of Rare Diseases
  72. Cardiovascular effects of calcium supplementation
    Ian R. Reid, Mark J Bolland, Alison Avenell, Andrew B. Grey · 2011 · Osteoporosis International
  73. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
    Athanasios D. Anastasilakis, Stergios A. Pοlyzos, Polyzois Makras · 2018 · European Journal of Endocrinology
  74. Management of Osteogenesis Imperfecta
    Stuart H. Ralston, Mark S. Gaston · 2020 · Frontiers in Endocrinology
  75. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab
    Michael S. Ominsky, Cesar R. Libanati, Qing‐Tian Niu, Rogely Waite Boyce, Paul J. Kostenuik, Rachel B. Wagman, Roland Baron, David W. Dempster · 2015 · Journal of Bone and Mineral Research
  76. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
    Daniele Santini, Giuseppe Perrone, Ilaria Roato, Laura Godio, Francesco Pantano, Donatella Grasso, Antonio Dello Russo, Bruno Vincenzi, Maria Elisabetta Fratto, Roberto Sabbatini et al. · 2010 · Journal of Cellular Physiology
  77. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B Jönsson, Oskar Ström, John A. Eisman, Αλεξάνδρα Παπαϊωάννου, Ethel S. Siris, Anna N.A. Tosteson, J. A. Kanis · 2010 · Osteoporosis International
  78. Stem Cell Therapy for Osteoporosis
    Ben Antebi, Gadi Pelled, Dan Gazit · 2014 · Current Osteoporosis Reports
  79. Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing
    Silvano Adami, Cesar R. Libanati, Steven Boonen, Steven Ron Cummings, Pei‐Ran Ho, Andrea Wang, Ethel S. Siris, Joseph M. Lane · 2012 · Journal of Bone and Joint Surgery
  80. Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial
    Kim Brixen, Roland D Chapurlat, Angela M. Cheung, Tony M. Keaveny, Thomas P. Fuerst, Klaus Engelke, Robert R. Recker, Bernard J. Dardzinski, Nadia Verbruggen, Shabana Ather et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
  81. Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
    Yuichiro Ukon, Takahiro Makino, Joe Kodama, Hiroyuki Tsukazaki, Daisuke Tateiwa, Hideki Yoshikawa, Takashi Kaito · 2019 · International Journal of Molecular Sciences
  82. Bone Mineral Density After Transitioning From Denosumab to Alendronate
    David L. Kendler, Arkadi A. Chines, Patricia Clark, Peter Robert Ebeling, Michael R. McClung, Yumie Rhee, Shuang Huang, Robert Kees Stad · 2019 · The Journal of Clinical Endocrinology & Metabolism
  83. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses
    Felicia Cosman, Shuang Huang, Michele McDermott, Steven Ron Cummings · 2020 · Journal of Bone and Mineral Research
  84. Population Pharmacokinetic Meta-Analysis of Denosumab in Healthy Subjects and Postmenopausal Women with Osteopenia or Osteoporosis
    Liviawati Sutjandra, Rachelle D. Rodriguez, Sameer Doshi, Mark Ma, Mark C. Peterson, Graham R. Jang, Andrew T. Chow, Juan José Pérez Ruixo · 2011 · Clinical Pharmacokinetics
  85. A Guide to Improving the Care of Patients With Fragility Fractures
    Susan V. Bukata, Benedict F. DiGiovanni, Susan M. Friedman, Harry A. Hoyen, Amy Kates, Stephen L. Kates, Simon C. Mears, Daniel Ari Mendelson, Fernando H. Serna, Frederick E. Sieber et al. · 2011 · Geriatric Orthopaedic Surgery & Rehabilitation
  86. Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?
    Tahir Masud, Neil Binkley, Steven Boonen, Marian T. Hannan · 2011 · Journal of Clinical Densitometry
  87. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
    Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., Zanchetta, J. R. · 2018 · Osteoporosis International
  88. Bone Loss After Denosumab: Only Partial Protection with Zoledronate
    Ian R. Reid, Anne M. Horne, Borislav Mihov, Greg D. Gamble · 2017 · Calcified Tissue International
  89. Pharmacological treatment of osteoporosis in the oldest old
    Anne-Marie Vandenbroucke, Frank P. Luyten, Johan Flamaing, Evelien Gielen · 2017 · Clinical Interventions in Aging
  90. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
    Zhanna E. Belaya, K. Yu. Belova, Elena Valer'evna Biryukova, Ivan Ivanovich Dedov, Larisa Konstantinovna Dzeranova, Oksana M. Drapkina, Alexander Vasil'evich Dreval', Т. A. Dubovitskaya, Е. N. Dudinskaya, Olga B. Ershova et al. · 2021 · Osteoporosis and Bone Diseases
  91. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
    Ghada El‐Hajj Fuleihan, Gregory A. Clines, Mimi I-Nan Hu, Claudio Marcocci, Mohammad Hassan Murad, Thomas Piggott, Catherine H. Van Poznak, Joy Y. Wu, Matthew T. Drake · 2022 · The Journal of Clinical Endocrinology & Metabolism
  92. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
    Joshua D. Hutcheson, Claudia Goettsch · 2023 · Circulation Research
  93. Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
    Tony M. Keaveny, Michael R. McClung, Harry K. Genant, José Zanchetta, David L. Kendler, Jacques P. Brown, Stefan Goemaere, Chris P. Recknor, Maria Luisa Brandi, Richard Eastell et al. · 2013 · Journal of Bone and Mineral Research
  94. Genetic Determinants of Trabecular and Cortical Volumetric Bone Mineral Densities and Bone Microstructure
    Lavinia Paternoster, Mattias Lorentzon, Terho J. Lehtimäki, Joel Eriksson, Mika A. P. Kähönen, Olli Tuomas Raitakari, Marika M. L. Laaksonen, Harri T. Sievänen, Jorma S.A. Viikari, Leo‐Pekka Lyytikäinen et al. · 2013 · PLoS Genetics
  95. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
    Fang Lv, Xiaoling Cai, Wenjia Yang, Leili Gao, Ling Chen, Jing Wu, Linong Ji · 2019 · Bone
  96. Romosozumab and antiresorptive treatment: the importance of treatment sequence
    Felicia Cosman, David L. Kendler, Bente Lomholt Langdahl, Benjamin Z. Leder, Edward Michael Lewiecki, Akimitsu Miyauchi, Maria Rojeski, Michele McDermott, Mary K. Oates, Cassandra E. Milmont et al. · 2022 · Osteoporosis International
  97. The Development of Molecular Biology of Osteoporosis
    Gao, Yongguang, Patil, Suryaji, Jia, Jingxian · 2021 · International Journal of Molecular Sciences
  98. Bone Disease in CKD: A Focus on Osteoporosis Diagnosis and Management
    Paul D. Miller · 2014 · American Journal of Kidney Diseases
  99. Antifracture Efficacy of Currently Available Therapies for Postmenopausal Osteoporosis
    Jean‐Yves Reginster · 2010 · Drugs
  100. Multicentric Carpotarsal Osteolysis Is Caused by Mutations Clustering in the Amino-Terminal Transcriptional Activation Domain of MAFB
    Andreas Zankl, Emma L. Duncan, Paul J. Leo, Graeme R. Clark, Evgeny A. Glazov, Marie‐Claude Addor, Troels Herlin, Chong Ae Kim, Bruno Leheup, Jim McGill et al. · 2012 · The American Journal of Human Genetics